English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background  The ePlex BCID Gram-Positive (GP) panel utilizes electrowetting technology to detect the most common causes of GP bacteremia (20 targets) and 4 antimicrobial resistance (AMR) genes in positive blood culture (BC) bottles. Rapid detection of intrinsic vancomycin resistance and acquired resistance genes ( mecA, mecC, vanA, vanB ) enables early optimization of antimicrobial therapy whereas early detection of common contaminants is expected to decrease unnecessary antibiotic utilization and hospitalizations.    Methods  In this prospective study, aliquots of BC bottles with GP bacteria detected on Gram stain (GS) (n=101) received standard of care (SOC) culture and antimicrobial susceptibility testing (AST). Additionally, samples were evaluated with the BCID-GP panel but only SOC results were reported in the EMR and available to inform clinical decisions. Patients were excluded if the sample was a subsequent culture in a persistent episode of bacteremia (n=17) or if the assay failed (n=4). Chart review was performed to evaluate the expected impact of the BCID-GP panel on the time to organism identification, AST results, and optimization of antimicrobial therapy.Results  A total of 80 patients were included in the final analysis (Table 1).  S. epidermidis  was the most common bacteria identified, followed by  S. aureus , and other coagulase-negative staphylococci. Thirty-nine patients with staphylococci (48.8%) had the  mecA  gene detected and 2 patients with  E. faecium  had the  vanA  gene detected. The BCID-GP panel saved a mean of 24.4 hours (h) to identification and 48.3h to susceptibility testing compared to standard methods across all patients. In 38 patients (47.5%), the BCID-GP panel result could have enabled an earlier change in antibiotic therapy. Table 2 highlights opportunities to optimize antimicrobial therapy 53.4h earlier for 16 (20%) patients with organisms expressing AMR genes, 29.2h earlier for 8 (10%) patients infected with organisms, such as streptococci, with very low resistance rates, and to stop antimicrobial therapy 42.9h earlier for 14 (17.5%) patients with contaminated blood cultures.Conclusion  The BCID-GP panel could have enabled earlier optimization or stopping of antibiotics in many patients with significant time savings compared to standard laboratory methods.Disclosures    Todd P. McCarty, MD ,  Cidara  (Grant/Research Support) GenMark  (Grant/Research Support, Other Financial or Material Support, Honoraria for Research Presentation) T2 Biosystems  (Consultant)  Sixto M. Leal, Jr., MD, PhD ,  Abnova  (Grant/Research Support) AltImmune  (Grant/Research Support) Amplyx Pharmaceuticals  (Grant/Research Support) Astellas Pharmaceuticals  (Grant/Research Support) CNINE Dx  (Grant/Research Support) GenMark Diagnostics  (Grant/Research Support, Other Financial or Material Support, Honoraria- Research Presentation) IHMA  (Grant/Research Support) IMMY Dx  (Grant/Research Support) JMI/Sentry  (Grant/Research Support) mFluiDx Dx  (Grant/Research Support) SpeeDx Dx  (Grant/Research Support) Tetraphase Pharmaceuticals  (Grant/Research Support)

open forum infectious diseases

1027. Earlier Is Better: Progress Toward Decreased Time to Optimal Therapy and Improved Antibiotic Stewardship for Gram-positive Bloodstream Infections Through Use of GenMark Dx ePlex system